Autres immunothérapies

Audrey Simonaggio; Aurélien Marabelle

doi:10.1016/S0007-4551(18)30397-7

Autres immunothérapies

Translated title of the contribution: Alternative immunotherapies

Audrey Simonaggio, Aurélien Marabelle

Research output: Contribution to journal › Article › peer-review

Abstract

Alternative Immunotherapies: Monoclonal antibodies targeted at immune checkpoint molecules such as PD-1, PD-L1, and CTLA-4 have revolutionized the field of oncology in a few years. This success is explained by the large spectrum of activity of these therapies (more than 30 different cancer types), and the durability of tumor responses which provide benefits in overall survival for patients. However, a majority of patients do not respond to these treatments and novel immune strategies are needed to overcome resistance to monotherapies. A compelling effort is ongoing with numerous novel immunotherapies being in clinical development. Beyond immunomodulatory antibodies, other immunotherapies (small inhibitory molecules, vaccines, cytokines, viruses, cells) are in clinical trials or have been already approved, not only targeting T-cells but also other immune cells, including innate immune cells. This review summarizes the recent advances obtained with these new therapies.

Translated title of the contribution	Alternative immunotherapies
Original language	French
Pages (from-to)	S121-S131
Journal	Bulletin du Cancer
Volume	105
DOIs	https://doi.org/10.1016/S0007-4551(18)30397-7
Publication status	Published - 1 Dec 2018

Access to Document

10.1016/S0007-4551(18)30397-7

Cite this

@article{bf3c290e72264200b8cacd2cbeaece3b,

title = "Autres immunoth{\'e}rapies",

abstract = "Alternative Immunotherapies: Monoclonal antibodies targeted at immune checkpoint molecules such as PD-1, PD-L1, and CTLA-4 have revolutionized the field of oncology in a few years. This success is explained by the large spectrum of activity of these therapies (more than 30 different cancer types), and the durability of tumor responses which provide benefits in overall survival for patients. However, a majority of patients do not respond to these treatments and novel immune strategies are needed to overcome resistance to monotherapies. A compelling effort is ongoing with numerous novel immunotherapies being in clinical development. Beyond immunomodulatory antibodies, other immunotherapies (small inhibitory molecules, vaccines, cytokines, viruses, cells) are in clinical trials or have been already approved, not only targeting T-cells but also other immune cells, including innate immune cells. This review summarizes the recent advances obtained with these new therapies.",

keywords = "Cancer, Immunotherapy",

author = "Audrey Simonaggio and Aur{\'e}lien Marabelle",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Masson SAS",

year = "2018",

month = dec,

day = "1",

doi = "10.1016/S0007-4551(18)30397-7",

language = "Fran{\c c}ais",

volume = "105",

pages = "S121--S131",

journal = "Bulletin du Cancer",

issn = "0007-4551",

}

TY - JOUR

T1 - Autres immunothérapies

AU - Simonaggio, Audrey

AU - Marabelle, Aurélien

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Alternative Immunotherapies: Monoclonal antibodies targeted at immune checkpoint molecules such as PD-1, PD-L1, and CTLA-4 have revolutionized the field of oncology in a few years. This success is explained by the large spectrum of activity of these therapies (more than 30 different cancer types), and the durability of tumor responses which provide benefits in overall survival for patients. However, a majority of patients do not respond to these treatments and novel immune strategies are needed to overcome resistance to monotherapies. A compelling effort is ongoing with numerous novel immunotherapies being in clinical development. Beyond immunomodulatory antibodies, other immunotherapies (small inhibitory molecules, vaccines, cytokines, viruses, cells) are in clinical trials or have been already approved, not only targeting T-cells but also other immune cells, including innate immune cells. This review summarizes the recent advances obtained with these new therapies.

AB - Alternative Immunotherapies: Monoclonal antibodies targeted at immune checkpoint molecules such as PD-1, PD-L1, and CTLA-4 have revolutionized the field of oncology in a few years. This success is explained by the large spectrum of activity of these therapies (more than 30 different cancer types), and the durability of tumor responses which provide benefits in overall survival for patients. However, a majority of patients do not respond to these treatments and novel immune strategies are needed to overcome resistance to monotherapies. A compelling effort is ongoing with numerous novel immunotherapies being in clinical development. Beyond immunomodulatory antibodies, other immunotherapies (small inhibitory molecules, vaccines, cytokines, viruses, cells) are in clinical trials or have been already approved, not only targeting T-cells but also other immune cells, including innate immune cells. This review summarizes the recent advances obtained with these new therapies.

KW - Cancer

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85059074554&partnerID=8YFLogxK

U2 - 10.1016/S0007-4551(18)30397-7

DO - 10.1016/S0007-4551(18)30397-7

M3 - Article

C2 - 30595193

AN - SCOPUS:85059074554

SN - 0007-4551

VL - 105

SP - S121-S131

JO - Bulletin du Cancer

JF - Bulletin du Cancer

ER -

Autres immunothérapies

Abstract

Access to Document

Other files and links

Cite this